Comparison of efficacies of bovine immune colostral antibody and each immunoglobulin class against verotoxin 2, flagellum and somatic cells of Escherichia coli O157:H7 in mice  by Seita, Tetsurou et al.
Journal of Microbiology, Immunology and Infection (2013) 46, 73e79Available online at www.sciencedirect.com
journal homepage: www.e- jmii .comORIGINAL ARTICLE
Comparison of efficacies of bovine immune colostral
antibody and each immunoglobulin class against
verotoxin 2, flagellum and somatic cells of
Escherichia coli O157:H7 in miceTetsurou Seita a, Takashi Kuribayashi a, Toshio Honjo b, Shizuo Yamamoto a,*a Laboratory of Immunology, School of Life and Environmental Science, Azabu University, Kanagawa, Japan
b Seminar on Environment, School of Life and Environmental Science, Azabu University, Kanagawa, Japan





VT2* Corresponding author. Laboratory
Sgamihara, Chuo-ku, Kanagawa 252-5
E-mail address: yamamoto@azabu
1684-1182/$36 Copyright ª 2012, Taiw
doi:10.1016/j.jmii.2012.01.002Purpose: The efficacy of bovine immune colostral (colostral) antibodies against verotoxin (VT)
2, flagellum and somatic cells of Escherichia coli (E. coli) O157:H7 in mice was determined.
Methods: Three major immunoglobulin (Ig) classes were isolated from the colostral antibody
against VT2 by affinity chromatography and were used for estimation. Mice inoculated with
VT2 were administered each Ig class from the colostral antibody, colostral antibody (colostral
whey containing antibody) or serum antibody against VT2 at 1 hour after VT2 inoculation.
Results: All control mice (20/20) died after administration of sterilized saline instead of the
colostral antibody. The survival rate was 93.3% (14/15) after administration of S-IgA or IgM
antibody, or colostral antibody. Survival rates for IgG antibody and serum antibody administra-
tion were 80% (12/15) and 60% (9/15), respectively. Serum concentrations of VT2, which was
absorbed from the small intestine in mice after administration of VT2 and colostral antibody,
were measured by fluorescence enzyme immunoassay (FEIA). Serum concentrations of VT2
after administration of colostral antibody were lower than those after administration of ster-
ilized saline. Mice inoculated with VT2-producing E. coli 157:H7 were administered anti-
flagellum or anti-somatic colostral antibodies. Survival rates for E. coli O157:H7-infected mice
administered the anti-flagellum and anti-somatic colostral antibodies were 52.4% (11/21) and
22.2% (4/18), respectively. Furthermore, survival rates increased to 89.5% (17/19) with
combined administration of anti-flagellum and anti-VT2 colostral antibodies.of Immunology, School of Life and Environmental Science, Azabu University, Fuchinobe 1-17-71,
201, Japan.
-u.ac.jp (S. Yamamoto).
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cells are effective against E. coli O157:H7 infection.
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A large outbreak of enterohemorrhagic Escherichia coli
(EHEC) O157:H7 occurred in Japan in July 1996,1e4 and food
poisonings caused by EHEC continue to be reported. Under
the Japanese Infection Diseases Control Law, patients with
EHEC infection are surveyed and 3878 symptomatic and
asymptomatic cases were reported in 2010 (Infection Agents
Surveillance Report. 2010. Enterohemorrhagic Escherichia
coli infection as of May 2010, Japan: http://www.nih.go.jp.
Accessed December, 2010). However, effective therapeutic
approaches using antibiotics and the prevention of compli-
cationsduetoverotoxin (VT) released fromEcolidisruptedby
antibiotics remain elusive.5e12
We previously reported that a bovine immune colostral
(colostral) antibody against VT is able to neutralize the
toxicity of VT13,14; the survival rates of mice infected with
E. coli O157:H7 producing VT2 improved after colostral
antibody administration and antibiotic treatment.13 It has
also been reported that bovine colostral antibody is resis-
tant to proteases in beagle dogs, as compared with serum
antibodies.14 Furthermore, S-IgA is more resistant to
proteases in beagle dogs than IgG or IgM.14 Bovine colostral
S-IgA and IgG antibodies thus resist proteases in the intes-
tines of beagle dogs and exhibit an effective neutralizing
activity against VT2 after oral administration. However,
comparisons of neutralizing efficacy for each immunoglob-
ulin class have yet to be performed.
In addition, we believe that adhesion of E. coli O157:H7
to the intestine would be more strongly inhibited by an
antibody against the flagellum. Thus, we prepared a bovine
colostral antibody against the flagellum, and investigated
whether this antibody inhibits adhesion of E. coli O157:H7.
Materials and methods
Bacterial strain and VT2
VT2-producing E. coli O157:H7 isolated from a human
patient was used in this study. Crude VT2 was obtained and
VT2 levels in culture medium were determined in accor-
dance with the method of Kuribayashi et al.13
Animals
A pregnant dairy cow (age Z 8 years), 3 months prior to
delivery, was used for the preparation of colostral antibody
against VT2, and a pregnant dairy cow (age Z 8 years), 4
months prior to delivery, was used for the preparation of
colostral antibody against the flagellum or somatic cells of
E. coli O157:H7. SPF ICR mice (Charles River Japan, Inc.,
Yokohama, Kanagawa, Japan) aged 3 weeks were used. All
mice were deprived of food beginning at 18 hours before
experiments.All experiments conformed to Japanese regulations
concerning animal care and use, as laid out in the Guide-
lines for Animal Experimentation (Japanese Association for
Laboratory Animal Science, 1987), and were approved by
the Institutional Animal Care and Use Committee of Azabu
University.
Purification of VT2
VT2 was purified from culture medium by affinity chroma-
tography using commercial mouse anti-VT2 A subunit mono-
clonal antibody (Capricorn Products LLC, Portland, ME, USA)-
coupled Sepharose 4B (GE Healthcare UK Ltd., Amersham
Place, Little Chalfont, Buckinghamshire, England).15
Quantitation of proteins
IgG, IgM and S-IgA concentrations in bovine immune colos-
trum were measured by single radial immunodiffusion using
diagnostic kits (Ecos Institute Co., Inc., Miyagi, Japan).
Protein concentrations of purified VT2 and isolated IgG, IgM
and S-IgA from bovine immune colostral whey were
measured using Coomassie Brilliant Blue G-250.16
Preparation of bovine colostral anti-VT2 antibody
Immunization was by daily administration of crude VT2 to
cows, in accordance with the procedure of Kuribayashi
et al.13,14 Colostral whey containing antibody was prepared
in accordance with the method of Kuribayashi et al.13
Bovine serum antibody against VT2 was obtained from
cows after 14 injections of purified VT2. Bovine anti-VT2
IgG antibody for fluorescence enzyme immunoassay (FEIA)
was isolated from bovine serum using a protein G column
(GE Healthcare UK Ltd.).
Neutralization test
Neutralization titers for colostral antibodies were measured
by neutralization tests using vero cells.17
Isolation of bovine colostral immunoglobulin
classes
Isolation of immunoglobulin classes from bovine immune
colostral whey was carried out by affinity chromatography.
Colostral IgG antibody was isolated from pre-treated bovine
colostral whey using a protein G column. Colostral IgM and
IgA antibodies were isolated from the non-adsorbed frac-
tions on protein G column chromatography using an anti-
bovine IgM (m) antibody (VMRD, Inc., Pullman, WA, USA)-
coupled sepharose 4B (GE Healthcare UK Ltd.) column and
an anti-bovine IgA (a) antibody (VMRD, Inc.)-coupled
sepharose 4B column, respectively.15 Identification of Ig
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out by the Ouchterlony method.
Identification of Ig classes isolated from bovine
colostrum
Identification of Ig classes isolated from bovine immune
colostrum was carried out by Ouchterlony agar diffusion,
according to standard procedures, with 1% agar (Wako Pure
Chemical Industries Ltd., Osaka, Japan) prepared with
veronal buffer (pH 8.6).
FEIA for measurement of VT2 in mouse sera
FEIA plates (Matrix Technologies Corporation, Hudson, NH,
USA) were coated with 100 mL (per well) of serially diluted
standard VT2 of known concentration or mouse sera. After
blocking with 1% ovalbumin in 0.05 M carbonate buffer (pH
9.6) at 37C for 1 hour and rinsing with washing buffer,
100 mL of bovine anti-VT2 IgG antibody isolated from serum
was added to all wells. After washing, the horseradish
peroxidase-conjugated rabbit anti-bovine IgG (MP Biomed-
icals, Inc., Solon, OH, USA) in PBS was added at 100 mL/
well. After washing, 100 mL of fluorescence substrate con-
sisting of a 9:1 mixture of Quanta Blu substrate solution and
Quanta Blu stable peroxidase solution (Pierce Biotech-
nology, IL, Rockford, USA) was added to all wells. Relative
fluorescence intensity (RFI) was measured using a fluorom-
eter (MTP-600F; Corona Electric Company, Ibaraki, Japan)
at 360 nm (excitation) and 450 nm (emission).
Preparation of anti-flagellum antibody against
E. coli O157:H7
Somatic cells of E. coli O157:H7 were obtained by centri-
fugation of culture supernatant at 1600g for 15 minutes.
Somatic cells of E. coli O157:H7 were injected into cows in
accordance with the procedure of Kuribayashi et al. E. coli
O157:H7 producing VT2 was centrifuged at 1600g for 20
minutes and heated at 121C for 15 minutes in order to
obtain somatic antigen. This somatic antigen and E. coli
O157:H7 were mixed with bovine immune colostrum and
left to stand at room temperature for 15 minutes. The anti-
flagellum antibody was obtained by centrifugation of this
mixture at 1600g for 15 minutes.
Preparation of antibody against somatic E. coli
O157:H7
The mixture of somatic antigen heated at 121C for 15
minutes and bovine immune colostral antibody were left to
stand for 1 hour at room temperature. The precipitates were
obtained by centrifugation, and glycine-HCl buffer (pH 2.3)
was added to the precipitates to yield anti-somatic antibody.
Indirect fluorescence antibody (IFA) titers and
specifities for anti-flagellum and anti-somatic
E. coli O157:H7
Indirect fluorescence antibody (IFA) for E. coli O157:H7 in
the anti-flagellum and anti-somatic colostral antibodieswere performed using the method of Killinger et al, with
some modification, i.e., with fluorescein-conjugated goat
anti-bovine immunoglobulin (Monosan, Uden, Netherlands).
Animal experiments
Efficacy of each immunoglobulin class: The neutralization
efficacy of each immunoglobulin class was evaluated in 95
mice. The evaluation methods were based on the methods
of Kuribayashi et al.13
Serum levels of VT2 in mice: Forty-eight mice were
divided into two groups, and VT2 was administered to each
group. At 1 hour after administration of VT2, colostral
antibody was administered to the colostral antibody group
and sterilized saline was administered to the control group.
Blood was collected at 2, 4, 8, 12, 16 and 24 hours after VT2
administration. At each time point, four mice were sacri-
ficed under anesthesia, and blood was collected.
Efficacy of anti-flagellum or anti-somatic colostral
antibody: Eighty mice were divided into four groups. Mice
in each group were inoculated with E. coli O157:H7
producing VT2 (2.5  108 CFU/mL). At 1 and 3 hours after
inoculation, each antibody was administered to the
respective groups of mice. Both the anti-flagellum antibody
and anti-VT2 antibody were prepared for administration
at equal volumes. Sterilized saline was administered to
the control group. Beginning at 6 hours after inoculation 3
times a day for 3 days, mice were administered fosfomysin
(FOM) at a dosage of 500 m/g body weight (Meiji Seika
Kiasha, Ltd., Tokyo, Japan) in order to disrupt E. coli
O157:H7 present in the intestine. Survival rates in each
group were observed for 2 weeks after inoculation.
Results
VT2 levels in culture medium
The agglutination titer of VT2 in culture medium on
reversed passive latex agglutination test was 1:64. After
the culture medium was concentrated, the agglutination
titer was 1:512. This agglutination titer corresponded to
approximately 800 ng/mL VT2, and the concentrated
culture medium was administered to mice for evaluation of
the neutralizing efficacy of each immunoglobulin class.
Neutralizing antibody titers of bovine colostra
and sera
The neutralizing antibody titer of colostrum obtained from
dairy cows immunized with VT2 was 1:128. The neutralizing
antibody titer of sera obtained from the same cow was 1:32.
These colostral and serum antibodies were administered to
mice for evaluation of their neutralizing efficacy against VT2.
Identification of Ig classes isolated from bovine
colostra
The antigenicities of Ig classes isolated from bovine
immune colostrum were identified. The Ouchterlony
patterns are shown in Fig. 1. The anti-bovine IgA, IgG and
Figure 1. Ouchterlony analysis of S-IgA, IgM and IgG, isolated from immunized bovine colostrum. A Z S-IgA; AA Z rabbit anti-
bovine IgA(a) antibody; M Z IgM; AM Z rabbit anti-bovine IgM(m) antibody; G Z IgM; AG Z sheep anti bovine IgG(g) antibody.
76 T. Seita et al.IgM sera, respectively, formed precipitation lines with the
IgA, IgG and IgM isolated from bovine immune colostrum.
Concentrations of Ig classes isolated from bovine
colostrum
The concentrations of IgG, S-IgA and IgM isolated from
bovine colostrum were 94, 17 and 5 mg/mL, respectively.
Each immunoglobulin antibody administered to mice was
adjusted based on these concentrations.
Identification of anti-flagellum and anti-somatic
antibodies against E. coli O157:H7
The specifities of anti-flagellum and anti-somatic E. coli
O157:H7 antibodies are shown in Fig. 2. IFA titer for the
anti-flagellum and anti-somatic antibodies against E. coli
O157:H7 were 1:16 and 1:16, respectively. These antibodies
were administered to mice after inoculation with E. coli
O157:H7.
Efficacy of bovine anti-VT2 colostral
immunoglobulin classes and anti-VT2 serum
antibody
The survival rates of mice administered VT2 after treat-
ment with bovine anti-VT2 colostral Ig classes and anti-Figure 2. Specificity of anti-flagellum (A) and anti-somatic (BVT2 serum antibody are shown in Table 1. Survival rates
were 93.3% after treatment with colostral S-IgA and IgM
antibodies and immune colostral whey groups. Survival
rates in the groups treated with colostral IgG antibody and
bovine serum antibody were 80.0% and 60.0%, respec-
tively. On the other hand, all mice in the control group
died.
The degree of intestinal bleeding with each immuno-
globulin class is shown in Table 2. Intestinal bleeding was
evaluated by visual inspection and was rated as follows:
negativeZ 0; minimalZ 1; moderateZ 2; and severeZ 3.
Of dead mice treated with sterilized physiological saline,
bovine immune colostral immunoglobulins and bovine
serum antibody, 84.4% showed intestinal bleeding scores of
2 or 3, with 95.0% of dead mice in the control group showing
scores of 2 or 3. In contrast, 33.3% of dead mice that had
been treated with bovine serum antibody showed scores of
2 or 3. In addition, 15.6% of dead mice did not show any
intestinal bleeding.
Serum levels of VT2 in mice
Serum levels of VT2 in mice after administration of VT2
are shown in Fig. 3. Serum levels of VT2 in the colos-
tral antibody group were lower than in the control
group, and significant differences were observed
between the colostral antibody and control groups at 8
and 12 hours.) antibodies against E. coli O157:H7 using the IFA method.
Table 1 Survival rates of VT2-administered mice treated with each immunoglobulin class of bovine anti-VT2 colostral and
serum antibodies
Time after administration Surviving mice treated with
S-lgA lgM lgG Colostrum1 Serum antibody2 Sterilized saline
1 day 15 15 15 15 12 19
2 days 14 15 15 15 12 7
3 days 14 15 15 15 9 2
4 days 14 14 13 14 9 1
5e14 days 14 14 12 14 9 0
Survival rates 93.3% (14/15) 93.3% (14/15) 80% (12/15) 93.3% (14/15) 60.0% (9/15) 0% (0/20)
1 Colostral whey containing antibody to VT2.
2 Bovine serum containing antibody to VT2.
S-IgA, IgM and IgG antibodies were isolated from bovine immune colostrum.
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antibodies against E. coli O157:H7
Survival rates of mice in each antibody group are shown in
Table 3. Several accidental deaths in each group were
observed after inoculation or administration of FOM.
Survival rate in the anti-flagellum antibody group was
higher than that in the anti-somatic antibody group. The
anti-flagellum and anti-VT2 antibody group showed the












E. coli O157:H7 infection is not generally treated using
antibiotics,8e11, as VT from E. coli O157:H7 disrupted by
antibiotics leads to complications such as hemolytic uremic
syndrome. A colostral antibody against rotavirus has been
developed and its efficacy has been confirmed.18 We
therefore prepared a colostral antibody against VT by
immunizing a cow with VT prior to pregnancy. This immune
colostral antibody was expected to neutralize the toxicity
of VT and inhibit VT absorption from the intestine. We
demonstrated the neutralizing efficacy of immune colostral
antibody against VT in weaning mice or beagle dogs.
Furthermore, the present immune colostral antibody was
confirmed to be resistant to proteases in the small intes-
tines. However, efficacy was evaluated by administration of
crude immune colostral antibody. The present study was
conducted in order to clarify the efficacy of each immu-





3þ 2þ 1þ 0 Total
Sterilized (Control group) 18 1 0 1 20
Colostral antibody 0 0 0 1 1
Colostral S-lgA antibody 0 1 0 0 1
Colostral lgM antibody 0 1 0 0 1
Colostral lgG antibody 1 0 0 2 3
Serum antibody 4 1 0 1 6Survival rates with S-IgA, IgM and colostral antibody
were similar in mice administered VT2. S-IgA isolated from
colostral antibody was found to have the highest resistance
to proteases in the intestines of beagle dogs,14 this may be
the reason for the higher survival rate seen with S-IgA. On
the other hand, we believe that IgM exists as a pentamer,
and has greater affinity for VT2 than S-IgA,19e21 despite its
lower activity than S-IgA in beagle dogs,14 and the
concentration of IgM was one-third that of S-IgA.14 The
survival rate with IgM was therefore similar to that with
S-IgA. The serum antibody showed the lowest survival rate,
and this result was correlated with the resistance to
protease in vivo. The differences in neutralizing efficacy on
passive immune examination in the present mice, may have
been due to differences in protease resistance in vivo.
These results suggest that S-IgA or IgM is able to neutralize
VT2 in the intestine. However, each immunoglobulin class
was individually administered to mice. Only small amounts
of antibody could be administered, as the mice used in the
present study were small. Higher survival rates would be
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Figure 3. Serum levels of VT2 in mice after administration of
VT2. Concentrations of VT2 in serum were measured by FEIA
(* p < 0.05).
Table 3 Survival rates of Escherichia coli O157:H7-infected mice treated with anti-flagellum or anti-somatic cell antibody
Time after
administration








1 day 17 15 19 18
2 days 13 11 17 16
3 days 13 10 17 16
4 days 13 10 17 9
5e14 days 11 4 17 3
Survival rates 52.4 % (11/21) 22.2 % (4/18) 89.5 % (17/19) 15.0 % (3/20)
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administration of crude colostral antibody against VT2, as
compared to control mice administered sterilized saline.
This suggests that absorption of VT2 from the intestine is
reduced by crude colostral antibody against VT2. This
decrease in VT2 absorption was presumed to prevent injury
to organs such as the kidney,22,23 and was therefore
considered to be one of the factors responsible for the
improved survival rates.
The flagellum of E. coli O157:H7 is an important factor
for adhesion to the intestine. We prepared a novel immune
colostral anti-flagellum antibody, and we expected that
E. coli O157:H7 infection would be prevented by inhibiting
E. coli O157:H7 adhesion to the intestine. The anti-
flagellum group showed an increased mice survival rate
when compared to the anti-somatic group. This improve-
ment of survival rate by administration of anti-flagellum
antibody was presumed to inhibit E. coli O157:H7 adhe-
sion to the intestine. Combined treatment with the anti-
flagellum antibody and the anti-VT2 antibody further
improved the survival rate, probably because simply inhib-
iting adhesion is only partially effective in limiting bacterial
colonization, while the VT2 released by disrupted E. coli
O157:H7 is neutralized by colostral anti-VT2 antibody.
Thus, combination treatment with these antibodies is
potentially useful against serious E. coli O157:H7 infections.
In conclusion, the immune colostral antibody against VT
and the anti-flagellum antibody may be able to prevent
serious complications in the treatment of E. coli O157:H7
infection.
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